Pfizer and BioNTech have begun enrollment for a clinical trial to test the safety and immune response of their Omicron-specific COVID-19 vaccine in adults aged up to 55, the companies said in a statement quoted by AFP on Tuesday.
Pfizer’s head of vaccine research, Kathrin Jansen, said in a statement that while current data showed that boosters against the original COVID strain continued to protect against severe outcomes with Omicron, the company was acting out of caution.
Read more